KR102761594B1 - 신규 핵산 분자 - Google Patents

신규 핵산 분자 Download PDF

Info

Publication number
KR102761594B1
KR102761594B1 KR1020207003234A KR20207003234A KR102761594B1 KR 102761594 B1 KR102761594 B1 KR 102761594B1 KR 1020207003234 A KR1020207003234 A KR 1020207003234A KR 20207003234 A KR20207003234 A KR 20207003234A KR 102761594 B1 KR102761594 B1 KR 102761594B1
Authority
KR
South Korea
Prior art keywords
protein
nucleic acid
subunit
domain
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003234A
Other languages
English (en)
Korean (ko)
Other versions
KR20200024905A (ko
Inventor
마리올라 포틴-믈레크제크
카트야 피들러
알렉산드라 코발치크
레지나 하이덴라이히
Original Assignee
큐어백 에스이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐어백 에스이 filed Critical 큐어백 에스이
Publication of KR20200024905A publication Critical patent/KR20200024905A/ko
Application granted granted Critical
Publication of KR102761594B1 publication Critical patent/KR102761594B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020207003234A 2017-07-04 2018-07-03 신규 핵산 분자 Active KR102761594B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/066676 2017-07-04
EPPCT/EP2017/066676 2017-07-04
PCT/EP2018/068015 WO2019008001A1 (en) 2017-07-04 2018-07-03 NEW NUCLEIC ACID MOLECULES

Publications (2)

Publication Number Publication Date
KR20200024905A KR20200024905A (ko) 2020-03-09
KR102761594B1 true KR102761594B1 (ko) 2025-02-03

Family

ID=59384128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003234A Active KR102761594B1 (ko) 2017-07-04 2018-07-03 신규 핵산 분자

Country Status (12)

Country Link
US (2) US10988754B2 (enExample)
EP (3) EP3648791A1 (enExample)
JP (2) JP7722629B2 (enExample)
KR (1) KR102761594B1 (enExample)
CN (1) CN111328287A (enExample)
AU (1) AU2018298422B2 (enExample)
BR (1) BR112019028280A2 (enExample)
CA (1) CA3066932A1 (enExample)
ES (1) ES3013993T3 (enExample)
RU (1) RU2020103379A (enExample)
SG (1) SG11201911430PA (enExample)
WO (1) WO2019008001A1 (enExample)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
KR20140102759A (ko) * 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
ES2969742T3 (es) 2012-03-27 2024-05-22 CureVac SE Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
CN110195072A (zh) 2013-08-21 2019-09-03 库瑞瓦格股份公司 狂犬病疫苗
ES2747762T3 (es) 2013-08-21 2020-03-11 Curevac Ag Vacuna contra el virus respiratorio sincitial (RSV)
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
DK4023755T5 (da) 2014-12-12 2024-07-29 CureVac SE Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
WO2016193206A1 (en) 2015-05-29 2016-12-08 Curevac Ag A method for producing and purifying rna, comprising at least one step of tangential flow filtration
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
US11684665B2 (en) 2015-12-22 2023-06-27 CureVac SE Method for producing RNA molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
MX2018009917A (es) 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
EP3468613A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
US11739335B2 (en) 2017-03-24 2023-08-29 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
EP4467196A3 (en) 2017-06-28 2025-06-25 The Cleveland Clinic Foundation Treatment of nervous system injury and neurodegenerative disorders and related conditions
CN119080881A (zh) * 2017-07-07 2024-12-06 伊玛提克斯生物技术有限公司 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
JP2021502079A (ja) 2017-11-08 2021-01-28 キュアバック アーゲー ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ）
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP4227319B1 (en) 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
IL279759B1 (en) 2018-06-28 2025-10-01 Tesla Automation GmbH Bioreactor for in vitro RNA transcription
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
SG11202106666UA (en) 2018-12-21 2021-07-29 Curevac Ag Methods for rna analysis
EP3683229A1 (en) * 2019-01-21 2020-07-22 Charité - Universitätsmedizin Berlin Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
CN111466338B (zh) * 2019-01-23 2022-03-22 中国科学院广州生物医药与健康研究院 Ddx5基因缺失的生精障碍小鼠模型及其构建方法
US20220177891A1 (en) * 2019-02-19 2022-06-09 Board Of Regents, The University Of Texas System Hipk inhibitors and methods of use thereof
CN109777783B (zh) * 2019-02-20 2023-07-04 上海尚泰生物技术有限公司 表达cxcr2的car-nk92细胞、制备方法及其应用
CN111620934B (zh) * 2019-02-26 2022-03-08 中国科学院遗传与发育生物学研究所 蛋白GmHSFB2b在调控植物黄酮类化合物积累中应用
CN110093419B (zh) * 2019-04-26 2023-10-27 北京大学深圳医院 环状rna的应用、试剂盒和药物组合物及其应用
EP3995147A4 (en) * 2019-07-04 2023-08-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. SUBSTANCE AND METHOD OF TREATMENT OF TUMORS
CN112175062B (zh) * 2019-07-05 2022-07-15 中国医学科学院基础医学研究所 Sft2b蛋白线性抗原表位以及其在精神分裂症诊断中的用途
WO2021041541A1 (en) * 2019-08-28 2021-03-04 The Board Of Trustees Of The Leland Stanford Junior University Modified circular rnas and methods of use thereof
JP2022553042A (ja) * 2019-10-21 2022-12-21 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの組成物、方法および使用
JP2023505737A (ja) * 2019-12-11 2023-02-10 アベリノ ラボ ユーエスエー インコーポレイテッド Ｒ１２４ｈ突然変異を備えたトランスフォーミング増殖因子ベータ誘導遺伝子の短鎖干渉ｒｎａを使用したアレル特異的サイレンシング
CN111057690A (zh) * 2019-12-23 2020-04-24 维塔恩(广州)医药有限公司 肿瘤相关基因braf突变相关抗原短肽及其应用
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN111647597B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027479表达的siRNA及其应用
CN111733158B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0003599表达的siRNA及其应用
CN111647598B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027477表达的siRNA及其应用
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
CN115803333A (zh) 2020-07-02 2023-03-14 生命技术公司 三核苷酸帽类似物、其制备和用途
CN111840303A (zh) * 2020-07-15 2020-10-30 天津大学 胞质羧肽酶抑制剂及其应用
CN111984622B (zh) * 2020-07-31 2023-10-31 上海派拉软件股份有限公司 Pap的配置及运行方法、装置、电子设备和存储介质
WO2022037692A1 (en) * 2020-08-21 2022-02-24 Peking University Circular rna vaccines and methods of use thereof
CN112011564A (zh) * 2020-09-04 2020-12-01 西南大学 新型隐球菌细胞核指示载体及其构建方法和应用
CN111973745B (zh) * 2020-09-08 2022-07-26 中国医科大学 Bap18在乳腺癌内分泌治疗抵抗中的应用
CN114225035B (zh) * 2020-09-09 2022-12-16 上海交通大学医学院 环状RNA Cwc27下调剂在制备预防和/或治疗阿尔茨海默病的药物中的应用
DE102020125457A1 (de) * 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
CN112574975B (zh) * 2020-09-30 2022-04-01 华南理工大学 甘油酯脂肪酶突变体g28c-p206c及其编码基因与应用
CN112050201B (zh) * 2020-10-10 2022-04-12 清华大学 一种异型炉膛结构的湍动流化床焚烧炉
CN112190719B (zh) * 2020-10-19 2023-07-04 重庆大学 一种钙调控机制紊乱的动物模型在视网膜病变中的应用
CN112375766B (zh) * 2020-12-02 2022-04-29 华南农业大学 一种水稻抗氧化能力相关基因brhis1及其应用
CN112480232B (zh) * 2020-12-14 2022-07-15 上海交通大学 一种生物活性肽vsladlqndevafr及其制备方法和应用
CN112961247A (zh) * 2020-12-17 2021-06-15 维亚生物科技(上海)有限公司 一种融合蛋白及其应用
CN112575003B (zh) * 2020-12-17 2022-02-15 中国农业科学院植物保护研究所 本氏烟hakai基因在调控植物抗病毒中的应用及转基因植物培育方法
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
CN112630449B (zh) * 2020-12-30 2022-10-18 广西壮族自治区水牛研究所 对水牛出生时间进行判断的血液外泌体标志物及其应用
CN112763714B (zh) * 2020-12-31 2022-07-01 徐州市中心医院 一种用于肝癌诊断的生物标志物及其检测方法
CN112662680B (zh) * 2020-12-31 2022-07-05 浙江大学 番茄黄化转绿基因SlRHBDD2及其应用
CN112794901B (zh) * 2021-01-08 2022-01-04 南通大学附属医院 一种抗smim15单克隆抗体及其应用
CN112362432B (zh) * 2021-01-12 2021-04-09 广州科方生物技术股份有限公司 一种通用于血清中tt3和tt4的解离剂及其制备方法
CN114762694B (zh) * 2021-01-13 2023-07-14 中国人民解放军军事科学院军事医学研究院 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
CN112626236A (zh) * 2021-01-14 2021-04-09 华南农业大学 与奶牛乳腺上皮细胞凋亡相关的circRNA标志物及其应用
CN112679596B (zh) * 2021-01-15 2022-03-15 武汉大学 一种内收蛋白的抗原肽及其抗体与应用
CN112574997B (zh) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
EP4291229A4 (en) * 2021-02-09 2025-03-26 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
CN112795642A (zh) * 2021-02-09 2021-05-14 四川大学华西医院 鉴定家族性渗出性玻璃体视网膜病变伴/不伴小头畸形的引物及其应用
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
CN113373129B (zh) * 2021-05-25 2022-07-26 湖北大学 一种原核生物来源的Mbp_Argonaute蛋白及其应用
CN113393900B (zh) * 2021-06-09 2022-08-02 吉林大学 基于改进Transformer模型的RNA状态推断研究方法
CN115491369B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Pdia3的表位肽及所述表位肽与热休克蛋白的复合物
CN113450872B (zh) * 2021-07-02 2022-12-02 南昌大学 磷酸化位点特异激酶的预测方法
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
WO2023049541A1 (en) * 2021-07-23 2023-03-30 Cassava Sciences, Inc. Blood-based diagnostic assays for alzheimer's disease
WO2023014598A2 (en) * 2021-08-03 2023-02-09 Inflammatix, Inc. Isothermal amplification-based diagnosis and treatment of acute infection
CN113846122B (zh) * 2021-08-16 2023-08-25 中国医学科学院医学生物学研究所 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN113533589B (zh) * 2021-09-16 2021-12-17 天九再生医学(天津)科技有限公司 一种分析外泌体电荷异质性的方法
CN114457052B (zh) * 2021-09-17 2024-02-27 厦门大学 一种抗肿瘤的多肽组合物及其应用
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
GB2615177A (en) 2021-11-29 2023-08-02 BioNTech SE Coronavirus vaccine
CN114134109B (zh) * 2021-12-10 2023-01-24 广州远想生物科技股份有限公司 Egf间充质干细胞外泌体的纯化方法
EP4450628A4 (en) * 2021-12-13 2025-10-22 Sml Biopharm Co Ltd NUCLEIC ACID EXPRESSION PLATFORM WITH INCREASED EXPRESSION EFFICIENCY
CN114262378B (zh) * 2021-12-20 2023-03-24 南京诺唯赞生物科技股份有限公司 一种omt的单克隆抗体及其制备方法
CA3243030A1 (en) * 2021-12-21 2025-02-26 Amgen Inc DCAF4L2 SPECIFIC T LYMPHOCYTE RECEPTORS
CN114276418B (zh) * 2021-12-28 2024-06-25 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114384032B (zh) * 2022-01-17 2023-07-14 云南大学 诺如病毒检测探针和非诊断目的检测诺如病毒的方法
US20250108134A1 (en) * 2022-01-28 2025-04-03 Beijing Changping Laboratory Circular rna vaccines and methods of use thereof
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
CN114621962B (zh) * 2022-03-21 2024-05-14 广西大学 花生AhBI-1基因VIGS沉默体系
US12416044B2 (en) * 2022-03-21 2025-09-16 Abclonal Science, Inc. T4 DNA ligase variants with increased ligation efficiency
CN114410607A (zh) * 2022-03-22 2022-04-29 上海威高医疗技术发展有限公司 嗜热羧酸酯酶突变体及其应用
CN119403568A (zh) * 2022-04-07 2025-02-07 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
US20250251394A1 (en) * 2022-04-12 2025-08-07 Concordia University Aptamer-based electrochemical drug detection assay
CN115219720A (zh) * 2022-05-20 2022-10-21 上饶师范学院 靶向分子atx在乙肝阳性肝癌中的应用及其研究方法
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用
CN114703287B (zh) * 2022-06-06 2022-08-12 江苏省肿瘤医院 CXorf56基因在治疗三阴性乳腺癌中的应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN114916502B (zh) * 2022-07-07 2023-06-16 电子科技大学 一种视网膜色素变性疾病模型的构建方法和应用
CN116286990A (zh) * 2022-09-08 2023-06-23 南开大学 特异性靶向肿瘤和转移抑制的细胞膜来源纳米囊泡的制备方法与应用
UY40490A (es) 2022-10-17 2024-04-30 Pfizer Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN116254253B (zh) * 2022-11-11 2024-06-28 浙大宁波理工学院 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用
CN115472216B (zh) * 2022-11-14 2023-03-24 神州医疗科技股份有限公司 基于数据集成的肿瘤跨适应症联合用药推荐方法和系统
CN116083353B (zh) * 2022-12-02 2025-10-17 唐颐生物医学(天津)有限公司 一种过表达Anxa1的脐带间充质干细胞外泌体及其制备方法和应用
CN115814605B (zh) * 2022-12-06 2024-04-12 浙江大学 一种废弃反渗透膜修复剂及修复方法
CN116271007B (zh) * 2022-12-26 2025-10-03 浙江大学 一种用于治疗炎症性肠病的药物
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物
CN116334083B (zh) * 2023-02-24 2025-06-20 青岛农业大学 花生U6启动子及其在花生CRISPR-Cas9基因编辑中的应用
CN116474080B (zh) * 2023-04-20 2023-12-22 新疆农垦科学院 一种细粒棘球绦虫表面展示型酿酒酵母口服疫苗及其构建方法和应用
NL2034658B1 (en) * 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden TIMP3-derived TEIPP neoantigens and uses thereof
CN116555286B (zh) * 2023-04-28 2024-05-14 昆明理工大学 三七富含脯氨酸蛋白基因PnPRPL1及其应用
CN116514115B (zh) * 2023-05-05 2025-05-13 大连医科大学 一种巯基烟酸与金纳米粒子修饰氧化石墨烯材料及其制备方法和应用
AU2024278682A1 (en) 2023-05-26 2025-11-27 CureVac SE Cancer antigens
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用
EP4484954A1 (en) * 2023-06-29 2025-01-01 Uniwersytet Gdanski Mhc class i restricted immunopeptide pattern for generation of anti-nsclc vaccines
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
CN117169519B (zh) * 2023-10-26 2024-01-30 艾康生物技术(杭州)有限公司 用于检测样本中tt3和/或tt4的解离剂和试剂盒
CN117230077B (zh) * 2023-11-13 2024-02-23 四川省医学科学院·四川省人民医院 Hakai基因在RP疾病模型构建中的应用及构建方法
WO2025103803A1 (en) * 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025140126A1 (en) * 2023-12-25 2025-07-03 Everest Medicines (China) Co., Ltd. Therapeutic ly6k mrna vaccine for cancer
WO2025146077A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025146130A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Therapeutic BIRC5 mRNA Vaccine for Cancer
WO2025148611A1 (zh) * 2024-01-12 2025-07-17 新牛（郑州）生物科技有限公司 肿瘤抗原肽融合蛋白及其组合物的基因工程化递送和应用
CN117986344B (zh) * 2024-02-05 2025-12-02 浙江大学 一种靶向线粒体核糖核酸酶p的多肽及应用
CN118516398B (zh) * 2024-02-26 2025-04-22 四川农业大学 水稻OsMED23基因、其编码蛋白及其应用
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒
KR20250148433A (ko) * 2024-03-29 2025-10-14 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
CN118006766B (zh) * 2024-04-09 2024-06-28 鄂尔多斯市中心医院（内蒙古自治区超声影像研究所） Pola2在诊断代谢综合征中的应用
CN118546871B (zh) * 2024-05-10 2025-05-06 未来智人再生医学研究院(广州)有限公司 一种人多能干细胞分化为间充质干细胞的方法
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
CN118460649B (zh) * 2024-07-10 2024-12-13 凯莱英医药集团（天津）股份有限公司 一种Vutrisiran的制备方法
CN118530376B (zh) * 2024-07-26 2024-11-26 英特菲尔(成都)生物制品有限责任公司 一种具有修复抗皱活性的弹性蛋白及其制备方法与应用
CN119082106B (zh) * 2024-07-30 2025-09-30 福建中医药大学 一种抑制pno1基因表达的核酸分子及相关产品和用途
CN118879730B (zh) * 2024-08-08 2025-03-21 宁波大学 小麦TaHAKAI基因在调控小麦黄花叶病抗性中的应用
CN119464240B (zh) * 2024-08-19 2025-11-07 浙江理工大学绍兴生物医药研究院有限公司 一种突变型高稳定的过氧化氢酶及其构建方法
CN119464217A (zh) * 2024-11-01 2025-02-18 天津外泌体科技有限公司 一种囊泡及其作为标准品的应用
CN119390756B (zh) * 2024-11-04 2025-12-09 南京大学 一类基于d构型二苯丙氨酸的拟肽及其应用
CN119120482B (zh) * 2024-11-08 2025-02-14 中国医学科学院医学生物学研究所 E3泛素连接酶rnf181基因表达抑制剂在制备预防和/或治疗hsv-1病毒感染药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US20030091590A1 (en) 2001-01-17 2003-05-15 Pomerantz Roger J. Recombinant rhabdoviruses as live-viral vaccines
WO2014100385A1 (en) * 2012-12-20 2014-06-26 Anthrogenesis Corporation Chimeric antigen receptors
WO2015082922A1 (en) 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
ATE417112T1 (de) * 1997-03-27 2008-12-15 Csl Ltd Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
WO2001008636A2 (en) 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
DE50214201D1 (de) 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
JP2005535627A (ja) * 2002-06-25 2005-11-24 シティ・オブ・ホープ アジュバント不含ペプチド・ワクチン
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CU23204A1 (es) 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
KR20070122563A (ko) 2005-04-19 2007-12-31 일라이 릴리 앤드 캄파니 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
HUE043492T2 (hu) * 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
CN101448848B (zh) * 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
SI2167523T1 (sl) 2007-06-19 2014-09-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Sinteza in uporaba anti-reverznih fosforotioatnih analogov kape obveščevalne RNA
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
MX2010008468A (es) 2008-01-31 2010-08-30 Curevac Gmbh Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
US8058069B2 (en) 2008-04-15 2011-11-15 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
CN105152939A (zh) 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CA2756996C (en) * 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof
US8467858B2 (en) 2009-04-29 2013-06-18 Tomophase Corporation Image-guided thermotherapy based on selective tissue thermal treatment
KR20210031549A (ko) 2009-05-05 2021-03-19 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EP3175844A1 (en) 2010-04-09 2017-06-07 Pacira Pharmaceuticals, Inc. Large diameter synthetic membrane vesicles
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
MX341989B (es) 2010-08-31 2016-09-09 Novartis Ag * Liposomas pequeños para el suministro de arn que codifica el inmunogeno.
JP5908477B2 (ja) 2010-08-31 2016-04-26 ノバルティス アーゲー タンパク質をコードするｒｎａのリポソームによる送達に適した脂質
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP4115875A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
PE20141520A1 (es) * 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
SG10201602456WA (en) 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
BR112014023898A2 (pt) 2012-03-27 2017-07-11 Curevac Gmbh moléculas de ácido nucleico artificiais compreendendo 5''utr top
ES2969742T3 (es) 2012-03-27 2024-05-22 CureVac SE Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
RU2651498C2 (ru) 2012-03-27 2018-04-19 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2854857B1 (en) 2012-05-25 2018-11-28 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
ES2747762T3 (es) 2013-08-21 2020-03-11 Curevac Ag Vacuna contra el virus respiratorio sincitial (RSV)
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
RU2016109938A (ru) 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
CN110195072A (zh) 2013-08-21 2019-09-03 库瑞瓦格股份公司 狂犬病疫苗
KR102354389B1 (ko) 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
US20170044268A1 (en) * 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
ES2963718T3 (es) * 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
BR112016026980B1 (pt) 2014-06-10 2022-05-03 Curevac Real Estate Gmbh Método para sintetizar uma molécula de rna de uma dada sequência
HRP20221536T1 (hr) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
WO2016011222A2 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
CA2961636A1 (en) * 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
DK4023755T5 (da) 2014-12-12 2024-07-29 CureVac SE Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
AU2015373404B2 (en) 2014-12-30 2021-09-09 CureVac SE Artificial nucleic acid molecules
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
SG11201708867UA (en) 2015-04-30 2017-11-29 Curevac Ag Immobilized poly(n)polymerase
SG11201708681SA (en) 2015-04-30 2017-11-29 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
DK3294326T3 (da) 2015-05-15 2021-05-31 Curevac Ag Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
US10729654B2 (en) 2015-05-20 2020-08-04 Curevac Ag Dry powder composition comprising long-chain RNA
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
WO2016193206A1 (en) 2015-05-29 2016-12-08 Curevac Ag A method for producing and purifying rna, comprising at least one step of tangential flow filtration
WO2016203025A1 (en) * 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
EP3332019B1 (en) 2015-08-07 2019-12-18 CureVac AG Process for the in vivo production of rna in a host cell
EP3825407A1 (en) 2015-08-10 2021-05-26 CureVac Real Estate GmbH Method of increasing the replication of a circular dna molecule
FI3954225T3 (fi) 2015-09-21 2023-12-28 Trilink Biotechnologies Llc Initioivia huputettuja oligonukleotidialukkeita 5’-huputettujen RNA:iden syntetisoimiseksi
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
CA3003103A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2017081082A2 (en) 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
US20180371392A1 (en) 2015-12-21 2018-12-27 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
US11684665B2 (en) 2015-12-22 2023-06-27 CureVac SE Method for producing RNA molecule compositions
AU2016377681B2 (en) 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
EP3414340B1 (en) 2016-02-12 2023-08-09 CureVac SE Method for analyzing rna
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
MX2018009917A (es) 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017162297A1 (en) 2016-03-24 2017-09-28 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
US20180237789A1 (en) 2016-04-16 2018-08-23 Jiangnan University Mortierella alpine uracil auxotroph with ura5 gene knocked out through homologous recombination
EP4487869A3 (en) 2016-04-22 2025-07-30 CureVac SE Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3452086A1 (en) 2016-05-04 2019-03-13 CureVac AG Influenza mrna vaccines
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
EP3468613A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
WO2017212008A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212006A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3468609A1 (en) 2016-06-09 2019-04-17 CureVac AG Cationic carriers for nucleic acid delivery
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
WO2018058088A1 (en) * 2016-09-26 2018-03-29 SOLA Biosciences, LLC Cell-associated secretion-enhancing fusion proteins
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091590A1 (en) 2001-01-17 2003-05-15 Pomerantz Roger J. Recombinant rhabdoviruses as live-viral vaccines
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2014100385A1 (en) * 2012-12-20 2014-06-26 Anthrogenesis Corporation Chimeric antigen receptors
WO2015082922A1 (en) 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Also Published As

Publication number Publication date
AU2018298422A1 (en) 2019-12-19
ES3013993T3 (en) 2025-04-16
CN111328287A (zh) 2020-06-23
BR112019028280A2 (pt) 2020-07-14
EP3424524A3 (en) 2019-02-27
EP3424524A2 (en) 2019-01-09
JP2023123739A (ja) 2023-09-05
CA3066932A1 (en) 2019-01-10
SG11201911430PA (en) 2020-01-30
EP3424524B1 (en) 2024-12-11
EP3648791A1 (en) 2020-05-13
RU2020103379A (ru) 2021-08-04
KR20200024905A (ko) 2020-03-09
US20190040378A1 (en) 2019-02-07
US20210198649A1 (en) 2021-07-01
RU2020103379A3 (enExample) 2021-12-07
EP4494652A3 (en) 2025-05-14
AU2018298422B2 (en) 2023-04-06
EP4494652A2 (en) 2025-01-22
JP7722629B2 (ja) 2025-08-13
JP2020530980A (ja) 2020-11-05
US10988754B2 (en) 2021-04-27
WO2019008001A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
KR102761594B1 (ko) 신규 핵산 분자
US11865084B2 (en) MERS coronavirus vaccine
US12201682B2 (en) Henipavirus vaccine
US12161711B2 (en) Lassa virus vaccine
US11723967B2 (en) Zika virus vaccine
TW202039534A (zh) KRAS變體mRNA分子
JP2020514370A (ja) 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
KR20160042935A (ko) 폐암 치료를 위한 조성물 및 백신
US12496335B2 (en) Zika virus vaccine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601